Medico Intercon. (539938)

Score breakdown: P/E: 0/3 · ROCE: 1/2 · Growth: 0/2 · Dividend: 0/1

Key Financials

Strengths

• Book value ₹38.64 per share is close to the market price of ₹45.49, so the P/B of 1.18 is not excessively stretched.
• ROCE of 13.82% suggests the operating platform generates reasonable returns before financing effects.
• Sales growth of 7.70% and latest quarterly revenue of ₹20 Cr show the business is still active and not shrinking.
• The market cap of ₹47 Cr keeps this a small, nimble operation; if profitability returns, the base is relatively modest.

Concerns

• Latest quarter net loss of ₹2 Cr, profit growth of -118.80%, and a P/E of 0.00 mean current earnings power is negative.
• ROE of 6.10% is too low for equity holders, and there is no dividend yield to compensate for the wait.
• Piotroski F-Score of 4/9 signals weak financial health and a higher chance of distress.
• Promoter holding is N/A, and the stock is trading at the top of its 52-week range, leaving little room for error.

AI Analysis

At first glance, ₹45.49 with a market cap of only ₹47 Cr looks like a small, forgotten stock. But Ben Graham taught me to start with earnings, not price. This is a trading and distribution business—essentially a commodity middleman. There is little pricing power and no durable competitive advantage. The numbers confirm my discomfort: latest quarterly sales of ₹20 Cr produced a net loss of ₹2 Cr. Annual profit growth is -118.80%, and the P/E of 0.00 is a sign that earnings have disappeared. A positive book value of ₹38.64 is helpful, but at ₹45.49 I am paying 1.18 times book. That is not a bargain; it is a premium for a business earning just 6.10% on equity. I prefer at least 12-15% returns on tangible equity; this one fails. ROCE at 13.82% looks respectable, but with debt-to-equity not disclosed, I cannot judge how much leverage is supporting that number. The Piotroski F-score of 4/9 is weak and tells me the financial health is poor. Sales growth of 7.70% is positive, but growth without profits destroys value. There is zero dividend yield, so shareholders are not being paid to wait. The stock sits at its 52-week high of ₹45.49, meaning market sentiment is already optimistic; I prefer pessimism. Promoter holding is not available, so I cannot assess alignment. In Graham's language, this is no margin of safety. A turnaround may emerge, but I need proof in the form of sustained quarterly profits before I invest a rupee.

Data from BSE/NSE filings. AI analysis is for educational purposes only — not investment advice. Scoring methodology · Disclaimer